File regulatory applications for a Phase 2 safety and efficacy study
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 12 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- 28 Apr 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Regulatory applications for a Phase 2 safety and efficacy study in patients with EB are in preparation with filings in several countries expected in the first half of calendar 2021”
What we found
Evidence strength A What the grades mean
The company announced on April 28, 2021, that it had filed Clinical Trial Applications for its Phase 2 study in Austria, Israel, and Serbia, meeting the first-half 2021 deadline.
-
A InMed Pharmaceuticals Inc. 10-K filed 2022-09-23
“April 28, 2021 – We announced that we filed Clinical Trial Applications (“CTAs”) in Austria, Israel and Serbia as part of a Phase 2 clinical trial of INM-755 (cannabinol) cream in Epidermolysis Bullosa (“EB”).” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- File
- Deliverable
- Regulatory applications for Phase 2 study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you InMed Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-INM-023742 · Corrections policy